Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group.

Importance: Gastrointestinal stromal tumor (GIST) follow-up is recommended by international guidelines, but data on the role of follow-up in patients with low relapse risk are missing. For these patients, the potential benefit of anticipating recurrence detection should be weighed against psychological burden and radiologic examination loads in terms of costs and radiation exposure. Objective: To evaluate the outcomes of guideline-based follow-up in low-risk GIST. Design, Setting, and Participants: This multi-institutional retrospective cohort study involving Italian Sarcoma Group reference institutions evaluated patients with GIST who underwent surgery between January 2001 and June 2019. Median follow-up time was 69.2 months. Data analysis was performed from December 15, 2022, to March 20, 2023. Patients with GIST at low risk according to Armed Forces Institute of Pathology criteria were included provided adequate clinical information was available: primary site, size, mitotic index, surgical margins, and 2 or more years of follow-up. Exposures: All patients underwent follow-up according to European Society for Medical Oncology (ESMO) guidelines. Main Outcomes and Measures: The primary outcome was the number of tests needed to identify a relapse according to ESMO guidelines follow-up plan. Secondary outcomes included relapse rate, relapse timing, disease-free survival (DFS), overall survival (OS), GIST-specific survival (GIST-SS), postrelapse OS, secondary tumor rates, and theoretical ionizing radiation exposure. An exploratory end point, new follow-up schedule proposal for patients with low-risk GIST according to the observed results, was also assessed. Results: A total of 737 patients (377 men [51.2%]; median age at diagnosis, 63 [range, 18-86] years) with low-risk GIST were included. Estimated 5-year survival rates were 95.5% for DFS, 99.8% for GIST-SS, and 96.1% for OS. Estimated 10-year survival rates were 93.4% for DFS, 98.1% for GIST-SS, and 91.0% for OS. Forty-two patients (5.7%) experienced disease relapse during follow-up (9 local, 31 distant, 2 both), of which 9 were detected after 10 or more years. This translated into approximately 1 relapse detected for every 170 computed tomography scans performed, with a median radiation exposure of 80 (IQR, 32-112) mSv per patient. Nongastric primary tumor (hazard ratio [HR], 2.09; 95% CI, 1.14-3.83; P = .02), and KIT mutation (HR, 2.77; 95% CI, 1.05-7.27; P = .04) were associated with a higher risk of relapse. Second tumors affected 187 of 737 patients (25%), of which 56 were detected during follow-up and represented the primary cause of death in these patients. Conclusions and Relevance: In this cohort study on patients affected by low-risk GISTs, the risk of relapse was low despite a follow-up across 10 or more years. These data suggest the need to revise follow-up schedules to reduce the anxiety, costs, and radiation exposure of currently recommended follow-up strategy.

Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions.

Effective treatment of advanced/metastatic bone and soft tissue sarcomas still represents an unmet medical need. Recent advances in targeted therapies have highlighted the potential of cyclin-dependent kinases (CDK) inhibitors in several cancer types, including sarcomas. CDKs are master regulators of the cell cycle; their dysregulation is listed among the "hallmarks of cancer" and sarcomas are no exception to the rule. In this review, we report both the molecular basis, and the potential therapeutic implications for the use of CDK inhibitors in sarcoma treatment. What is more, we describe and discuss the possibility and biological rationale for combination therapies with conventional treatments, target therapy and immunotherapy, highlighting potential avenues for future research to integrate CDK inhibition in sarcoma treatment.

Being the ultimate travel companion of a patient with uterine leiomyosarcoma.

Uterine fibroids are difficult to distinguish from malignant masses using standard ultrasonography; and morcellation carries the risk of disseminating occult cancer in a small but relevant group of women with an undetected uterine malignancy. In this context, we follow the progress of a woman diagnosed with uterine leiomyosarcoma after suboptimal initial surgery for an assumed fibroid. Evidence is reviewed that guided multidisciplinary tumor board decisions about optimal management approaches after local seeding and development of distant metastases, and informed treatment selection at each line of therapy. As the case study illustrates, choice of treatment for advanced soft tissue sarcomas frequently involves finding an appropriate balance between the efficacy and toxicity of available options, aiming to allow patients to maintain their normal lives.

Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report.

We report the case of a 51 year-old patient affected by an advanced uterine leiomyosarcoma treated with eribulin as fourth-line therapy. The patient, with a previous history of leiomyomas of the myometrium, had undergone total hysterectomy for repeated metrorrhagias. After 7 years, metastases in the liver, bone and lung were documented. A fine needle liver biopsy demonstrated leiomyosarcoma metastasis. The patient was treated with first-line doxorubicin chemotherapy; after six cycles, disease progression was observed. A second-line trabectedin chemotherapy and a third-line gemcitabine chemotherapy were performed; no objective responses were seen after two cycles. The patient was then treated with eribulin on the basis of an EORTC Phase II trial showing preliminary activity in uterine leiomyosarcoma. After six cycles, CT scan showed partial remission of liver lesion. Disease progression was observed after nine cycles with eribulin, without severe side effects and preserving a good quality of life.

Immediate effects of a distal gait modification during stair descent in individuals with patellofemoral pain.

Background: Knee pain during stair managing is a common complaint among individuals with PFP and can negatively affect their activities of daily living. Gait modification programs can be used to decrease patellofemoral pain. Immediate effects of a stair descent distal gait modification session that intended to emphasize forefoot landing during stair descent are described in this study. Objectives: To analyze the immediate effects of a distal gait modification session on lower extremity movements and intensity of pain in women with patellofemoral pain during stair descent. Method: Nonrandomized controlled trial. Sixteen women with patellofemoral pain were allocated into two groups: (1) Gait Modification Group (n = 8); and 2) Control Group (n = 8). The intensity of pain (visual analog scale) and kinematics of knee, ankle, and forefoot (multi-segmental foot model) during stair descent were assessed before and after the intervention. Results: After the gait modification session, there was an increase of forefoot eversion and ankle plantarflexion as well as a decrease of knee flexion. An immediate decrease in patellofemoral pain intensity during stair descent was also observed. Conclusion: The distal gait modification session changed the lower extremity kinetic chain strategy of movement, increasing foot and ankle movement contribution and decreasing knee contribution to the task. An immediate decrease in patellofemoral pain intensity during stair descent was also observed. To emphasize forefoot landing may be a useful intervention to immediately relieve pain in patients with patellofemoral pain during stair descent. Clinical studies are needed to verify the gait modification session effects in medium and long terms.

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.

BACKGROUND: Trabectedin is an alkylating drug with a unique mechanism of action causing single-strand and double-strand DNA breaks that activate DNA damage-response pathways. Based on our preclinical data, we hypothesised that poly(ADP-ribose) polymerase 1 (PARP1) inhibitors might be an ideal partner of trabectedin and aimed to assess the safety, identify the recommended phase 2 dose, and explore preliminary signs of activity of trabectedin and olaparib combination treatment in patients with bone and soft-tissue sarcoma. METHODS: We did an open-label, multicentre, phase 1b study, recruiting patients from the national Italian sarcoma network aged 18 years and older with histologically confirmed bone and soft-tissue sarcoma progressing after standard treatments with Eastern Cooperative Oncology Group performance status of 1 or less. In a classic 3 + 3 design, patients received a 24 h infusion of trabectedin on day 1 and olaparib orally twice a day in 21-day cycles across six dose levels (trabectedin 0·675-1·3 mg/m2 every 3 weeks; olaparib 100-300 mg twice a day from day 1 to 21). Intermediate dose levels were permitted to improve safety and tolerability. The primary endpoint was determination of the recommended phase 2 dose (the maximum tolerated dose). Safety and antitumour activity were assessed in all patients who received at least one dose of the study drugs. We report the results of the dose-escalation and dose-expansion cohorts. The trial is still active but closed to enrolment, and follow-up for patients who completed treatment is ongoing. This trial is registered with ClinicalTrials.gov, number NCT02398058. FINDINGS: Between Nov 17, 2014, and Jan 30, 2017, of 54 patients assessed for eligibility, we enrolled 50 patients: 28 patients in the dose-escalation cohort and 22 patients in the dose-expansion cohort. Patients received a median of four cycles of treatment (IQR 2-6; range 1-17 [the patients who received the highest number of cycles are still on treatment]) with a median follow-up of 10 months (IQR 5-23). Considering all dose levels, the most common grade 3-4 adverse events were lymphopenia (32 [64%] of 50 patients), neutropenia (31 [62%]), thrombocytopenia (14 [28%]), anaemia (13 [26%]), hypophosphataemia (20 [40%]), and alanine aminotransferase concentration increase (9 [18%]). No treatment-related life-threatening adverse events or deaths occurred. One (2%) patient interrupted treatment without progression without reporting any specific toxicity. Observed dose-limiting toxicities were thrombocytopenia, neutropenia for more than 7 days, and febrile neutropenia. We selected intermediate dose level 4b (trabectedin 1·1 mg/m2 every 3 weeks plus olaparib 150 mg twice a day) as the recommended phase 2 dose. Seven (14%; 95% CI 6-27) of 50 patients achieved a partial response according to Response Evaluation Criteria In Solid Tumors 1.1. INTERPRETATION: Trabectedin and olaparib in combination showed manageable toxicities at active dose levels for both drugs. Preliminary data on antitumour activity are encouraging. Two dedicated phase 2 studies are planned to assess activity of this combination in both ovarian cancer (EudraCT2018-000230-35) and soft-tissue sarcomas. FUNDING: Italian Association for Cancer Research, Italian Sarcoma Group, Foundation for Research on Musculoskeletal and Rare Tumors, and Italian Ministry of Health.

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.

BACKGROUND: Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action. It binds to minor groove of DNA inducing single- and double-strand-breaks. These kinds of damage lead to the activation of PARP1, a first-line enzyme in DNA-damage response pathways. We hypothesized that PARP1 targeting could perpetuate trabectedin-induced DNA damage in tumor cells leading finally to cell death. METHODS: We investigated trabectedin and PARP1 inhibitor synergism in several tumor histotypes both in vitro and in vivo (subcutaneous and orthotopic tumor xenografts in mice). We searched for key determinants of drug synergism by comparative genomic hybridization (aCGH) and gene expression profiling (GEP) and validated their functional role. RESULTS: Trabectedin activated PARP1 enzyme and the combination with PARP1 inhibitors potentiated DNA damage, cell cycle arrest at G2/M checkpoint and apoptosis, if compared to single agents. Olaparib was the most active PARP1 inhibitor to combine with trabectedin and we confirmed the antitumor and antimetastatic activity of trabectedin/olaparib combination in mice models. However, we observed different degree of trabectedin/olaparib synergism among different cell lines. Namely, in DMR leiomyosarcoma models the combination was significantly more active than single agents, while in SJSA-1 osteosarcoma models no further advantage was obtained if compared to trabectedin alone. aCGH and GEP revealed that key components of DNA-repair pathways were involved in trabectedin/olaparib synergism. In particular, PARP1 expression dictated the degree of the synergism. Indeed, trabectedin/olaparib synergism was increased after PARP1 overexpression and reduced after PARP1 silencing. CONCLUSIONS: PARP1 inhibition potentiated trabectedin activity in a PARP1-dependent manner and PARP1 expression in tumor cells might be a useful predictive biomarker that deserves clinical evaluation.

Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.

BACKGROUND: Follow-up aims to precociously identify recurrences, metastases or treatment-related adverse events so as to undertake the appropriate therapy. Guidelines admit lack of knowledge on optimal surveillance schedule, but suggest follow-up based on experts' opinion and risk stratification. To identify the impact, if any, of regular follow-up, we interrogated our prospectively collected database whether early detection of recurrences affected both clinical management and, likely, the outcome. PATIENTS AND METHODS: We required information to be available on primary surgery and ≥3°years of follow-up for non-recurring patients. We analysed recurrence characteristics (asymptomatic versus symptomatic, low- versus high tumour burden) and computed tomography (CT) scan counts to detect one recurrence. Kaplan-Meier method estimated recurrence-free survival (RFS), post-recurrence progression-free survival (PR-PFS), and disease-specific overall survival (OS). Comparisons used Hazard ratios (HR) with 95% confidence intervals (CIs). Multivariate analyses employed the Cox proportional hazards model. All tests were two-sided. RESULTS: Between 01/2001 and 12/2012 we found 233 study-eligible patients. Estimated 5- and 10-year RFS were 61.8% and 50.4%, respectively. After a 68-month median follow-up, we observed 94 (40.3%) recurrences [73/94 (77.7%) asymptomatic versus 21/94 (22.3%) symptomatic and 45/94 (47.9%) low- versus 49/94 (52.1%) high tumour burden]. Multivariate analysis revealed that symptomatic and high tumour burden recurrences were highly predictive of both worse PR-PFS (HR:3.19, P < 0.001; HR:2.80, P = 0.003, respectively) and OS (HR:3.65, P < 0.001; HR:2.38, P = 0.026, respectively). Finally, 29 second (primary) cancers were detected during follow-up. CONCLUSIONS: Regular follow-up detects recurrences at an earlier stage and may be associated with a better PR-PFS and OS for these patients. In the absence of randomised trials, these evidences support follow-up effort and cost.

Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.

Leiomyosarcoma represents about 24% of all soft tissue sarcomas and can originate from retroperitoneum, uterus, or extremities. Adequate local control may be achieved with surgery and radiotherapy. In the presence of unresectable metastases either doxorubicin- or gemcitabine-based chemotherapy is the standard of treatment. Nevertheless, prognosis remains poor regardless of the selected chemotherapy regimen, and new effective therapeutic agents for patients with advanced leiomyosarcoma are needed. Trabectedin, a promising new DNA-damaging agent with a mechanism of action that is different from that of traditional alkylating agents, is approved in Europe for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents and in combination with pegylated liposomal doxorubicin (PLD) for the treatment of patients with relapsed platinum-sensitive ovarian cancer. We present a case of a 76-year-old patient with progressive metastatic lung lesions from a previously resected primary leiomyosarcoma of the thigh and moderate renal failure, who achieved 17 months of disease stability during third-line treatment with trabectedin. Trabectedin was not associated with any cumulative toxicity and was consistently well tolerated for a total of 22 treatment cycles. Current evidence on trabectedin is also presented.

Clinical rearfoot and knee static alignment measurements are not associated with patellofemoral pain syndrome / Medidas clínicas estáticas do retropé e joelho não estão associadas à síndrome da dor patelofemoral

The aim of the present study was to investigate the association between the patellofemoral pain syndrome and the clinical static measurements: the rearfoot and the Q angles. The design was a cross-sectional, observational, case-control study. We evaluated 77 adults (both genders), 30 participants with patellofemoral pain syndrome, and 47 controls. We measured the rearfoot and Q angles by photogrammetry. Independent t-tests were used to compare outcome continuous measures between groups. Outcome continuous data were also transformed into categorical clinical classifications, in order to verify their statistical association with the dysfunction, and χ2 tests for multiple responses were used. There were no differences between groups for rearfoot angle [mean differences: 0.2º (95%CI -1.4-1.8)] and Q angle [mean differences: -0.3º (95%CI -3.0-2.4). No associations were found between increased rearfoot valgus [Odds Ratio: 1.29 (95%CI 0.51-3.25)], as well as increased Q angle [Odds Ratio: 0.77 (95%CI 0.31-1.93)] and the patellofemoral pain syndrome occurrence. Although widely used in clinical practice and theoretically thought, it cannot be affirmed that increased rearfoot valgus and increased Q angle, when statically measured in relaxed stance, are associated with patellofemoral pain syndrome (PFPS). These measures may have limited applicability in screening of the PFPS development.

O objetivo deste estudo foi investigar se existe associação entre a síndrome da dor patelofemoral e as medidas clínicas estáticas: os ângulos do retropé e Q. Foi realizado um estudo observacional, transversal, caso-controle, no qual foram avaliados 77 adultos (ambos os sexos), 30 participantes com síndrome da dor patelofemoral e 47 controles. Foram medidos os ângulos do retropé e Q, por meio da fotogrametria. Testes t para amostras independentes foram usados para comparações dos resultados das variáveis contínuas entre os grupos. Os resultados das variáveis contínuas foram transformados em classificações clínicas categóricas, para verificar a associação estatística com a disfunção, e o teste do χ2 para respostas múltiplas também foi utilizado. Não houve diferença entre os grupos para o ângulo do retropé [média da diferença: 0,2º (IC95% -1,4-1,8)] e ângulo Q [média da diferença: -0,3º (IC95%-3,0-2,4). Não houve associação entre o ângulo do retropé [Odds Ratio: 1,29 (IC95% 0,51-3,25)], assim como entre o ângulo Q [Odds Ratio: 0.77 (IC95% 0,31-1,93)] e a ocorrência da síndrome da dor patelofemoral. Apesar de serem teoricamente justificadas e amplamente utilizadas na prática clínica fisioterapêutica, não pode-se afirmar que as medidas dos ângulos do retropé e Q, quando mensuradas em posição ortostática, estão associadas com a ocorrência da síndrome da dor patelofemoral. Essas medidas podem ter aplicabilidade limitada na triagem desta disfunção.

Influence of patellofemoral pain syndrome on plantar pressure in the foot rollover process during gait.

BACKGROUND: Patellofemoral Pain Syndrome is one of the most common knee disorders among physically active young women. Despite its high incidence, the multifactorial etiology of this disorder is not fully understood. OBJECTIVES: To investigate the influence of Patellofemoral Pain Syndrome on plantar pressure distribution during the foot rollover process (i.e., the initial heel contact, midstance and propulsion phases) of the gait. MATERIALS AND METHODS: Fifty-seven young adults, including 22 subjects with Patellofemoral Pain Syndrome (30 ± 7 years, 165 ± 9 cm, 63 ± 12 kg) and 35 control subjects (29 ± 7 years, 164 ± 8 cm, 60 ± 11 kg), volunteered for the study. The contact area and peak pressure were evaluated using the Pedar-X system (Novel, Germany) synchronized with ankle sagittal kinematics. RESULTS: Subjects with Patellofemoral Pain Syndrome showed a larger contact area over the medial (p = 0.004) and central (p = 0.002) rearfoot at the initial contact phase and a lower peak pressure over the medial forefoot (p = 0.033) during propulsion when compared with control subjects. CONCLUSIONS: Patellofemoral Pain Syndrome is related to a foot rollover pattern that is medially directed at the rearfoot during initial heel contact and laterally directed at the forefoot during propulsion. These detected alterations in the foot rollover process during gait may be used to develop clinical interventions using insoles, taping and therapeutic exercise to rehabilitate this dysfunction.

Influence of patellofemoral pain syndrome on plantar pressure in the foot rollover process during gait

BACKGROUND: Patellofemoral Pain Syndrome is one of the most common knee disorders among physically active young women. Despite its high incidence, the multifactorial etiology of this disorder is not fully understood. OBJECTIVES: To investigate the influence of Patellofemoral Pain Syndrome on plantar pressure distribution during the foot rollover process (i.e., the initial heel contact, midstance and propulsion phases) of the gait. MATERIALS AND METHODS: Fifty-seven young adults, including 22 subjects with Patellofemoral Pain Syndrome (30 ± 7 years, 165 ± 9 cm, 63 ± 12 kg) and 35 control subjects (29 ± 7 years, 164 ± 8 cm, 60 ± 11 kg), volunteered for the study. The contact area and peak pressure were evaluated using the Pedar-X system (Novel, Germany) synchronized with ankle sagittal kinematics. RESULTS: Subjects with Patellofemoral Pain Syndrome showed a larger contact area over the medial (p = 0.004) and central (p = 0.002) rearfoot at the initial contact phase and a lower peak pressure over the medial forefoot (p = 0.033) during propulsion when compared with control subjects. CONCLUSIONS: Patellofemoral Pain Syndrome is related to a foot rollover pattern that is medially directed at the rearfoot during initial heel contact and laterally directed at the forefoot during propulsion. These detected alterations in the foot rollover process during gait may be used to develop clinical interventions using insoles, taping and therapeutic exercise to rehabilitate this dysfunction.

Medial contact and smaller plantar loads characterize individuals with Patellofemoral Pain Syndrome during stair descent.

OBJECTIVES: To investigate plantar pressure distribution in individuals with and without Patellofemoral Pain Syndrome during the support phase of stair descent. DESIGN: Observational case-control study. PARTICIPANTS: 30 young adults with Patellofemoral Pain Syndrome and 44 matched controls. MAIN OUTCOME MEASURES: Contact area, peak pressure and pressure-time integral (Novel Pedar-X system) were evaluated in six plantar areas (medial, central and lateral rearfoot; midfoot; medial and lateral forefoot) during stair descent. RESULTS: Contact area was greater in the Patellofemoral Pain Syndrome Group at medial rearfoot (p = 0.019) and midfoot (p < 0.001). Subjects with Patellofemoral Pain Syndrome presented smaller peak pressures (p < 0.001). CONCLUSION: The pattern of plantar pressure distribution during stair descent in Patellofemoral Pain Syndrome subjects was different from controls. This seems to be related to greater medial rearfoot and midfoot support. Smaller plantar loads found in Patellofemoral Pain Syndrome subjects during stair descent reveal a more cautious motor pattern in a challenging task.

A influência da ocupação profissional na flexibilidade global e nas amplitudes angulares dos membros inferiores e da lombar / The influence of occupation on overall flexibility and lower limb and lumbar range of motion

O desenvolvimento tecnológico no ambiente de trabalho gerou um aumentono tempo em que os indivíduos permanecem sentados enquanto trabalhamem escritórios. Isto pode estar influenciando negativamente capacidades físicas inatas como a flexibilidade da cadeia posterior do corpo, porém poucos são os estudos que avaliaram a influência do trabalho nesta capacidade física. Esta avaliação pode contribuir para intervenção precoce e paralela à atividade ocupacional, prevenindo disfunções musculoesqueléticas. O objetivo foi verificar se a atividade profissionaldetermina alguma modificação na flexibilidade global da cadeia posterior na postura de flexão do tronco e analisar os segmentos corporais contribuidores desta modificação. Participaram do estudo 24 mulheres saudáveis e sedentárias, entre 18 e 55 anos, que trabalhavam em manutenção (n=13) e em escritório (n=11). Foram avaliados o teste do terceiro dedo ao solo (fita métrica) e os ângulos articulares tíbio-társico, do joelho, do quadril, da lombar e a técnica de Chaffin Modificadapor meio da fotogrametria (software SAPo) na postura de flexão do tronco. Os grupos foram comparados por meio de teste t (?=5%). Mulheres que trabalham em escritório mostraram maiores distâncias do terceiro dedo ao solo (p=0,0518) e técnica de Chaffin Modificada significativamente menor . (p=0,0134), enquanto os ângulos tíbio- tarsico e do quadril mostraram valores marginalmente maiores nestas mulheres (p=0,0609 e p= 0,0713, respectivamente). Mulheres que trabalhampredominantemente na posição sentada apresentam menor flexibilidade global da cadeia posterior quando comparadas com as que realizam um trabalho que exige flexão cíclica do tronco. Sugere-se que os ângulos tíbio-tarsico e quadril, em conjunto, são os segmentos corporais que contribuem para esta menor flexibilidade.

The technological development in the working environment has prolongedsitting time for office employees. This prolonged sitting time may negatively influence innate physical capacities such as flexibility of the posterior chain; however, few studies have evaluated the influence of occupation on this physical capacity. This assessment might contribute to establish an early intervention approach, in parallel to the occupational activity, in order to prevent musculoskeletal dysfunctions. The aim of this study wasto determine whether occupational activity influences posterior chain muscle flexibility during trunk-flexed posture and to analyze the body segments that are responsible for any flexibility changes. Twenty-four healthy women aged 18 to 55 years, who worked in cleaning and maintenance (n=13) and in offices (n=11), participated in the study.The following measurements were obtained to evaluate trunk flexion: fingertip-to-floor distance test (measuring tape), tibiotarsal angle, knee extension/flexion angle, hip angle, lumbar angle, and modified Chaffin technique (digital photogrammetry using the SAPo software). The groups were compared using the independent t-test. Women working inoffices presented the worst fingertip-to-floor test result (p=0.0518) and a lower modified Chaffin technique value (p=0.0134), whereas their tibiotarsal and hip angles were marginally greater (p=0.0609 and p=0.0713, respectively). Women who mainly work seatedpresented lower overall flexibility of the posterior chain muscles than women who perform occupations that require cyclic flexion of the trunk. The tibiotarsal and hip angles seem to be the body segments responsible for this reduction in flexibility.

Força reação do solo durante a marcha com uso do tênis e sandália plataforma / Ground reaction force during gait with shoes and high-heel sandal

O objetivo deste estudo foi analisar a força reação do solo durante a marcha em cadência auto-selecionada, comparando as características entre a marcha descalça e com o uso de sandálias de salto plataforma e tênis esportivo. A amostra constituiu-se de 8 mulheres com média de idade de 22,9 (4,1) anos. A força reação do dolo foi adquirida com uma plataforma de força da AMTI e analisada no Origin v 6..0. Os resultados demonstraram um aumento do primeiro e do segundo picos verticais de força com o uso de sandália em relação à marcha descalça de 1,09 (0,06) PC para 1,18 (0,07) PC, diminuição do pico passivo de 0,61 (0,12) PC para 0,40 (0,16) PC e sua taxa de crescimento de 33,64 (16,91) PC/s para 16,19 (4,93) PC/s. A taxa de crescimento do primeiro pico de força diminuiu, mas não apresentou diferenças significativas de 7,98 (1,78) PC/s para 7,86 (3,82) PC/s. Essa diminuição das taxas de crescimento e aumento dos picos de força com o uso de sandália sugerem aumento de sobrecarga nas articulações dos membros inferiores, resultado principalmente da rigidez do solado e da instabilidade provocada pela elevação do centro de gravidade, justificando a diminuição de velocidade verificada. A menor magnitude do primeiro pico da FRS vertical de 1,14 (0,05) PC, com a utilização do tênis demonstra que na comparação com a sandália cujo primeiro pico foi de 1,18 (0,07) PC/s, a rigidez do solado é fator determinante para a magnitude desta variável. Esses resultados deveriam ser considerados para o desenvolvimento e a produção de sandálias com salto que promovessem maior conforto aos usuários

The purpose of this study was to analyze the ground reaction force during gait in auto-selected cadence, comparing the characteristic of barefoot gait between wearing of high-heel sandal and the wearing of sport shoes. The sample was constituted with 8 women with average age of 22,9(4,1) years old. The ground reaction force was acquired with a force platform by AMTI and analyzed with the Origin v 6.0. The results showed an increase of the first and second force vertical peaks with the wearing of sandal comparing to barefoot gait of 1,09 (0,06)BW to 1,18(0,07)BW, reduction of passive peak from 0,61(0,12)BW to 0,40(0,16)BW and it’s growth rate from 33,64(16,91)BW/ s to 16,19(4,93)BW/s. The growth rate of the first force peak decreased, but didn’t show significant differences from 7,98 (1,78)BW/s to 7,86 (3,82)BW/s. This reduction of the growth rate and increase of the force peaks on the wearing sandals situation suggests an increase on overload of the lower extremities, mainly caused by rigid-soled and instability generated by gravity center raise, justifying the decrease of speed encountered. The first peak’s minor magnitude of the vertical GRF of 1,14(0,05)BW verified on the sport shoes situation when comparing to the first peak’s when wearing the sandals 1,18(0,07)BW suggests that the rigid-soled is determinant factor for this variable magnitude. These results should be considered for development and production of high-heel sandals that would promote more comfort for the users.

The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005.

Nearly 29,000 scientists from all over the world gathered at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). The programme included the presentation of new data encompassing all the fields of cancer research, including cancer prevention, treatment and biology. Special sessions were added to summarise and discuss achievements in the field of translational research on biologically targeted therapies. Rational drug design based on tumour biology and genetics represents a promising strategy to overcome the limitations of conventional chemotherapy. Increased knowledge in the field of molecular oncology, genetics and progress in technology are revolutionising tumour classification, prognostication, prediction and therapy. However, at present, for most of the diseases, improvements brought about by the newer therapies are small, although clinically meaningful. This review will briefly address some of the most interesting data presented at ASCO 2005.